Analysis of a Novel Cluster V Mycobacteriophage EniyanLRS and its Therapeutically Relevant LysB

Imagine the world of bacteria as a bustling, fortified city. Some of these cities, like those built by Mycobacterium bacteria, are notoriously hard to conquer. They wear a thick, waxy armor that makes them nearly invisible to standard antibiotics, and when they team up in slimy, protective communities called "biofilms," they become even tougher. This is a major problem for doctors because these super-bacteria cause stubborn infections that are hard to cure, especially when they become resistant to multiple drugs.

Enter the heroes of this story: bacteriophages (or just "phages"). Think of phages as tiny, specialized viruses that are essentially biological snipers. They don't attack humans or animals; they only hunt specific bacteria. They land on a bacterial city, inject their genetic instructions, hijack the factory inside, and eventually burst the city open to release a new army of viruses. But there's a twist: to get out, the phage uses special "demolition enzymes" called endolysins. These enzymes act like molecular crowbars, prying open the bacterial walls from the inside. Scientists are now asking: Can we take these demolition tools out of the virus and use them as medicines on their own? If we can, we might have a new way to smash open those tough, drug-resistant bacterial fortresses without the side effects of traditional antibiotics.

The Story of EniyanLRS: A Tiny Virus and Its Super-Tool

In this study, a team of researchers from India went on a scavenger hunt in the soil of a tuberculosis hospital in New Delhi. They were looking for a specific type of phage that could hunt down Mycobacterium bacteria. What they found was a new, unique virus they named EniyanLRS.

The New Hunter
EniyanLRS is a member of a rare group of phages called "Cluster V." Imagine a family tree where most branches are crowded with cousins, but this one is a quiet, exclusive club with only five known members. EniyanLRS is the newest addition to this club. When the scientists looked at it under a powerful electron microscope, they saw it has a classic "siphovirus" shape: a round head (about 58.56 nanometers wide) attached to a very long, non-contractile tail (about 221.515 nanometers long). It's like a tiny submarine with an extra-long periscope.

This virus is a tough cookie. It can survive in temperatures ranging from a chilly 4°C up to a warm 55°C, and it can handle acidic or basic environments (pH 2 to 10) without falling apart. Most importantly, it successfully infects and destroys two types of bacteria: M. smegmatis (a common lab model) and M. fortuitum (a nasty, drug-resistant germ that causes skin and lung infections).

The Genetic Blueprint
The researchers decoded the virus's entire instruction manual (its genome). It's a long string of DNA, about 78,536 base pairs long. One of the coolest things they found was that EniyanLRS carries its own "translation kit." It has 24 tiny helper molecules called tRNAs. Since the virus's genetic code is slightly different from its host bacteria's code, these helpers ensure the virus can build its proteins quickly and efficiently, even if the host tries to slow it down. It's like a visitor bringing their own dictionary to a foreign country so they don't get stuck trying to read the local signs.

The team also checked the virus's "criminal record." They looked for any genes that would make it dangerous to humans or help it hide inside bacteria (a process called lysogeny). They found nothing. No weapons, no hiding spots, and no resistance to antibiotics. This suggests EniyanLRS is a "lytic" virus, meaning it attacks, kills, and leaves immediately—a very safe profile for a potential therapy.

The Two Demolition Tools: LysA vs. LysB
Like many phages, EniyanLRS carries two demolition enzymes, named LysA and LysB, to break out of the bacteria. The researchers made copies of these enzymes in the lab to see which one was the real hero.

• LysA (The Moderate Worker): This enzyme has a complex structure with parts that act like a lysozyme and a chitinase. In test tubes, it showed some activity, but when the scientists tried to use it to kill bacteria directly, it failed. It couldn't break through the tough, waxy outer wall of the bacteria. It's like having a key that fits the door but can't turn because the lock is too rusty.
• LysB (The Star Performer): This enzyme is an "esterase," meaning it cuts specific chemical bonds. When the team tested LysB, it was a total success. It acted like a molecular crowbar, slicing through the waxy armor of the bacteria.
  • On its own: LysB could dissolve bacterial cultures over time. After 24 hours, it stopped the growth of M. smegmatis by 83.2% and M. fortuitum by 79.7%.
  • On the surface: When they looked at the bacteria under a microscope after LysB treatment, the cells looked like popped balloons—wrinkled, clumped, and broken.
  • Against Biofilms: This is where LysB really shined. Biofilms are like bacterial cities protected by a slime shield. LysB managed to reduce the size of these biofilms by 62.77% for M. smegmatis and 41.91% for M. fortuitum. It didn't just kill the bacteria; it tore down their protective city walls.

The Resistance Test
A big worry with any treatment is that the bacteria might evolve to fight back. The researchers tested this by letting the bacteria grow alongside the virus for a long time (up to 122 hours). At a high dose of the virus, the bacteria stayed crushed and didn't grow back. Even when the bacteria eventually started to grow a little at lower doses, the scientists took those survivors and tested them again. They were still just as vulnerable to the virus as before. This suggests that EniyanLRS is a very stable hunter that doesn't easily lose its target.

What This Means
The study concludes that while the virus itself is a fascinating new member of a rare family, the real star of the show is its LysB enzyme. It is a powerful, safe, and effective tool that can break open drug-resistant bacteria and destroy their protective biofilms. The researchers suggest that LysB could be a promising candidate for a new type of medicine to treat stubborn mycobacterial infections, offering a fresh approach to a problem that current antibiotics are struggling to solve.